¼¼°èÀÇ Áٱ⼼Æ÷ Á¦´ëÇ÷ ½ÃÀå
Stem Cell Umbilical Cord Blood
»óǰÄÚµå : 1795370
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 127 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Áٱ⼼Æ÷ Á¦´ëÇ÷ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 77¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 26¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Áٱ⼼Æ÷ Á¦´ëÇ÷ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 19.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 77¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀǾàǰ ÃÖÁ¾»ç¿ëÀº CAGR 21.5%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 42¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¬±¸±â°ü ÃÖÁ¾»ç¿ë ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 17.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6¾ï 8,350¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 18.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Áٱ⼼Æ÷ Á¦´ëÇ÷ ½ÃÀåÀº 2024³â¿¡ 6¾ï 8,350¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 12¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 18.7%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 18.5%¿Í 17.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 14.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Áٱ⼼Æ÷ Á¦´ëÇ÷ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¦´ëÇ÷ Áٱ⼼Æ÷¿¡ ´ëÇÑ °ü½ÉÀ» ºÒ·¯ÀÏÀ¸Å°´Â °ÍÀº ¹«¾ùÀϱî?

Á¶Ç÷Àü±¸¼¼Æ÷¿Í °£¿±Àü±¸¼¼Æ÷¸¦ dzºÎÇÏ°Ô ÇÔÀ¯Çϰí ÀÖ´Â Á¦´ëÇ÷ Áٱ⼼Æ÷´Â Áß¿äÇÑ Àç»ýÀÇ·á µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ±× ¿ëµµ´Â Ç÷¾× Áúȯ, ¸é¿ª °áÇÌ, ÀϺΠ´ë»ç¼º ÁúȯÀÇ Ä¡·á¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù. Ãâ»ý ½Ã ÅÈÁÙ Ç÷¾×À» äÃëÇÏ¿© ÀºÇà¿¡ º¸°üÇÏ´Â °ÍÀº °¡Á·¿¡°Ô Àû±ØÀûÀÎ °Ç°­ °ü¸® ¿É¼ÇÀÌ µÇ¾î ÀÚ°¡ ¶Ç´Â µ¿Á¾ À̽ÄÀÇ °¡´É¼ºÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÓ»óÀǵéÀº Á¦´ëÇ÷Àº °ÅºÎ¹ÝÀÀÀÌ Àû°í, ºñħ½ÀÀûÀÌ¸ç ¹è¾ÆÁٱ⼼Æ÷¿¡ ´ëÇÑ ³í¶õÀ» ÇÇÇÒ ¼ö ÀÖ¾î À±¸®ÀûÀ¸·Îµµ ¿ëÀÌÇÏ´Ù°í ¸»ÇÕ´Ï´Ù. °ø°ø Á¦´ëÇ÷ ÀºÇà°ú ¹Î°£ Á¦´ëÇ÷ º¸°ü ¼­ºñ½º´Â »êºÎÀΰú ¼¾ÅÍ¿Í Çù·ÂÇÏ¿© ¼öÁý ÇÁ·ÎÅäÄÝÀ» °£¼ÒÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦´ëÇ÷Àº ½Å°æÇÐ, ÀÚ°¡¸é¿ªÁúȯ, Á¶Á÷¼öº¹ µî »õ·Î¿î Ä¡·á¹ýÀ» À§ÇÑ Áٱ⼼Æ÷ °ø±Þ¿øÀ¸·Î ¿¬±¸µÇ°í ÀÖ¾î ±âÁ¸ Ç÷¾×ÇÐÀÇ Æ²À» ³Ñ¾î¼± È®ÀåµÈ ÆÄÀÌÇÁ¶óÀÎÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

ÅÈÁÙ Ç÷¾×ÀÇ Ã¤Ãë¿Í º¸Á¸Àº ±â¼ú ¹ßÀü¿¡ µû¶ó °³¼±µÇ°í ÀÖ´Â °ÍÀϱî?

DMSO°¡ ¾ø´Â µ¿°á º¸È£Á¦, ÀÚµ¿ Á¦¾îµÈ µ¿°á ¼Óµµ, ÃÖÀûÈ­µÈ º¸Á¸ ½Ã½ºÅÛ µî ÷´Ü µ¿°áº¸Á¸ ¼Ö·ç¼ÇÀº ÇØµ¿ ÈÄ ¼¼Æ÷ÀÇ »ýÁ¸À²À» ³ôÀÔ´Ï´Ù. ÇÏÀ̽º·çDz ÇÁ·Î¼¼½Ì Ç÷§ÆûÀº Ç¥ÁØÈ­µÈ ¿ëÀû °¨¼Ò, ÀûÇ÷±¸ Á¦°Å, CD34+ ³óÃàÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. µðÁöÅÐ ÃßÀûÀº äÃë ŰƮ¿¡¼­ º¸°ü¼Ò±îÁö ¿£µå Åõ ¿£µå »ùÇà ÃßÀû¼ºÀ» º¸ÀåÇϰí, ÀºÇàÀÌ ±ÔÁ¦ °¨»ç ¹× ÀÎÁõ ±âÁØÀ» ÁؼöÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ÀüÀÚ ÀÇ·á ±â·Ï°úÀÇ ÅëÇÕÀ» ÅëÇØ ÀÇ»ç´Â °¡¿ë¼º, ÀûÇÕ¼º ±âÁØ, Á¶Á÷ ÀûÇÕ¼º º¸°í¼­¸¦ ½Å¼ÓÇÏ°Ô È®ÀÎÇÒ ¼ö ÀÖ¾î ÀÌ½Ä Àü ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÏ°í °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿Ö °¡Á·°ú º´¿øÀº Á¦´ëÇ÷ ÀºÇàÀ» ¹Þ¾ÆµéÀ̴°¡?

¼Ò¾Æ ¸¸¼ºÁúȯ ¹× À¯ÀüÁúȯÀÇ Áõ°¡·Î ¿¹¹æÀû ¾ÈÀüÀåÄ¡·Î¼­ Á¦´ëÇ÷ÀºÇà¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ºÎ¸ðµéÀº ÀºÇà¿¡ º¸°üµÈ Á¦´ëÇ÷À» ÀÚ½ÅÀÇ ÀÚ³à¿Í °¡±î¿î ģôµé¿¡°Ô ¸Å¿ì °¡Ä¡ ÀÖ´Â »ý¹°ÇÐÀû ÀÚ»êÀ¸·Î ¿©±â°í ÀÖ½À´Ï´Ù. ¹Î°ü ÆÄÆ®³Ê½ÊÀ» ÅëÇÑ ¹ðÅ· ¸ðµ¨ÀÇ ¹ßÀüÀº °æÁ¦ÀûÀ¸·Î ¿©À¯°¡ ¾ø´Â °¡Á·µµ Á¶»ç Á¢±ÙÀÌ °¡´ÉÇÑ °ø°ø ¹ðÅ·À» Áö¿øÇÒ ¼ö ÀÖ°ÔÇÔÀ¸·Î½á ÇüÆò¼ºÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÓ»óÀÇ¿Í À̽ļ¾ÅÍ´Â ¼¼Æ÷ ¼ö°¡ ¸¹°í Ç׿ø ÀûÇÕ¼ºÀÌ °¡Àå ÁÁÀº Á¦´ëÇ÷ ´ÜÀ§¸¦ ¼±È£ÇÕ´Ï´Ù. °ø±Þ¾÷üµéÀÌ Áö¿ø Ȱµ¿°ú ±³À° ÇÁ·Î±×·¥À» È®´ëÇÔ¿¡ µû¶ó Á¦´ëÇ÷ÀÇ Ä¡·á °¡´É¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

Á¦´ëÇ÷ Áٱ⼼Æ÷ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

Áٱ⼼Æ÷ Á¦´ëÇ÷ ½ÃÀåÀÇ ¼ºÀåÀº ÷´Ü Àú¿Â ±â¼ú, Ä¡·á »ç¿ë »ç·ÊÀÇ È®´ë, ÀÇ·á Á¤Ã¥ÀÇ ¹ßÀü°ú °ü·ÃµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. FDA°¡ ½ÂÀÎÇÑ 20°³ ÀÌ»óÀÇ Ä¡·á¹ý°ú ½Å°æ, ÀÚ°¡¸é¿ª, ´ë»ç ÀûÀÀÁõ¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀÇ Áõ°¡·Î ¼ö¿ä°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. °­È­µÈ ³Ãµ¿º¸Á¸ ±â¼úÀº Àå±âÀûÀÎ »ýÁ¸¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϰí, ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÕ´Ï´Ù. À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì µîÀÇ Áö¿ª¿¡¼­´Â Á¤ºÎÀÇ Àå·ÁÃ¥°ú º¸Çè Àû¿ë Á¤Ã¥À¸·Î ÀÎÇØ ¹ðÅ· µµÀÔÀÌ È°¹ßÇÏ°Ô ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ºÐ¸¸¼¾ÅÍ, ÀºÇà, ¿¬±¸±â°ü °£ÀÇ ÆÄÆ®³Ê½ÊÀº ¼öÁý ¹°·ù¸¦ °£¼ÒÈ­Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, Á¦´ëÇ÷ÀÇ Ä¡·áÀû °¡Ä¡¿¡ ´ëÇÑ »çȸÀû ÀνÄÀÇ Áõ°¡¿Í ÀÎÁõµÈ Á¦´ëÇ÷ ÀºÇà¿¡ ´ëÇÑ ºê·£µå ½Å·Ú°¡ ¹Î°£ ¹× °ø°ø º¸°ü ¸ðµÎ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÃÖÁ¾»ç¿ëÀÚ(ÀǾàǰ ÃÖÁ¾»ç¿ëÀÚ, Á¶»ç ÃÖÁ¾»ç¿ëÀÚ, º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¹ÙÀÌ¿À¹ðÅ© ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Stem Cell Umbilical Cord Blood Market to Reach US$7.7 Billion by 2030

The global market for Stem Cell Umbilical Cord Blood estimated at US$2.6 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2024-2030. Pharmaceuticals End-Use, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Research Institutes End-Use segment is estimated at 17.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$683.5 Million While China is Forecast to Grow at 18.7% CAGR

The Stem Cell Umbilical Cord Blood market in the U.S. is estimated at US$683.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.5% and 17.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global Stem Cell Umbilical Cord Blood Market - Key Trends & Drivers Summarized

What’s Driving Interest in Umbilical Cord Blood Stem Cells?

Umbilical cord blood stem cells, rich in hematopoietic and mesenchymal progenitors, have emerged as vital regenerative medicine tools. Their applications span treatments for blood disorders, immune deficiencies, and some metabolic diseases. Collecting and banking cord blood at birth has become a proactive healthcare choice for families, offering a potential autologous or allogeneic transplant source. Clinicians rely on the cells’ lower rejection rates and ethical ease-as collection is non-invasive and avoids embryonic stem cell controversies. Public cord blood banks and private storage services are collaborating with obstetric centers to simplify collection protocols. Additionally, cord blood is being explored as a stem cell source for emerging therapies in neurology, autoimmune disorders, and tissue repair, indicating an expansion pipeline beyond traditional hematology.

Are Technological Improvements Enhancing Collection and Storage?

Advanced cryopreservation solutions- using DMSO-free cryoprotectants, automated controlled-rate freezing, and optimized storage systems-are increasing cell viability post-thaw. High-throughput processing platforms are enabling standardized volume reduction, red blood cell depletion, and CD34+ enrichment. Digital tracking ensures end-to-end sample traceability-from collection kit to storage vault-helping banks comply with regulatory audits and accreditation standards. Integration with electronic health records allows physicians to quickly verify availability, matching criteria, and histocompatibility reports-facilitating pre-transplant decision-making and improving outcomes.

Why Are Families and Clinics Embracing Cord Blood Banking?

The rise in chronic and genetic pediatric disorders has elevated interest in cord blood banking as a preventative safeguard. Parents view banked cord blood as a high-value biological asset for their child and immediate family. Advances in public-private partnership banking models allow families without means to support research-accessible public banking, promoting equity. Clinicians and transplant centers prioritize cord blood units with high cell counts and optimal antigen matching. As suppliers expand outreach and educational programs, awareness around banked cord blood’s therapeutic potential is increasing.

What’s Powering the Growth in the Cord Blood Stem Cell Market?

The growth in the stem cell umbilical cord blood market is driven by several factors related to advanced cryogenic technology, expanded therapeutic use cases, and evolving healthcare policies. Over two dozen FDA-approved therapies and increasing clinical trials for neurological, autoimmune, and metabolic indications are broadening demand. Enhanced cryopreservation techniques ensure long-term viability and efficacy, enhancing patient outcomes. Government incentives and insurance coverage policies in regions like Europe, Asia-Pacific, and North America are supporting banking adoption. Partnerships between birthing centers, banks, and research institutions are streamlining collection logistics. Finally, growing public awareness of cord blood’s therapeutic value and branding trust in accredited banks are fueling both private and public storage.

SCOPE OF STUDY:

The report analyzes the Stem Cell Umbilical Cord Blood market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Pharmaceuticals End-Use, Research Institutes End-Use, Hospitals End-Use, Biobanks End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â